Key points from article :
BioAge Labs announced the initiation of another Phase 2 trial targeting COVID-19.
Identified prostaglandin D2 DP1 pathway as a key target for immune aging.
Study will evaluate the efficacy and safety of BGE-175 to treat COVID-19 in patients aged 60 or older.
Counteracts immunosenescence and improves both adaptive and innate immunity.
“BGE-175 could allow older patients to more effectively fight off COVID-19,” - Kristen Fortney, CEO of BioAge.
“Almost completely protects older mice against lethality from COVID-19," - Fortney.
“Because some variants of SARS-CoV-2 are vaccine-resistant, it is important to develop COVID-19 treatments like BGE-175,” - Stanley Perlman, professor at the University of Iowa.
“...to boost immune cell function while preventing dangerous overreaction,”- Paul Rubin, Chief Medical Officer.
Will also measure BGE-175’s effect on levels of inflammatory markers.
Previous clinical trials demonstrated it to be safe and well-tolerated in more than 2,400 study participants.
